Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shared Control: Novel Trial Design Works In COVID, But Will Sponsors Buy In?

Executive Summary

COVID-19 has helped demonstrate the viability of platform trials with a shared control arm. That model is easier to extol than it is for sponsors to embrace, especially outside of crisis mode.

You may also be interested in...

The US FDA And The Dog That Didn’t Bark

Commissioner Hahn’s role in the EUA for convalescent plasma has understandably roiled the world of FDA watchers. But what about the EUA that FDA still has not granted as a treatment for COVID-19?

COVID-19 Puts Spotlight On Clinical Trial Networks: 'We Really Need Them Right Now'

Duke-Margolis' Mark McClellan touts the advantages networks have over individual operations, citing the dexamethasone RECOVERY trial, and notes need for real-world evidence infrastructure.

Missing Data: One Long-Term Lesson From US FDA Action On Hydroxychloroquine

Politicization of COVID-19 treatments is one of the unexpected wrinkles amid an unprecedented pandemic. But one lesson from the hydroxychloroquine experience in the US is more typical if still troubling: almost no one followed the rules on reporting follow-up data.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts